IGF-1LR3

<p><strong>IGF-1LR3 (Insulin-like Growth Factor 1 Long Arg3)</strong> is a synthetic 83-amino-acid analog of human insulin-like growth factor 1 (IGF-1) engineered with two deliberate modifications: a 13-amino-acid N-terminal extension sequence and a glutamic acid-to-arginine substitution at position 3. These changes dramatically reduce IGF-1LR3 binding affinity for insulin-like growth factor binding proteins (IGFBPs), the six serum proteins that sequester approximately 97–99% of endogenous IGF-1 in the bloodstream. By evading IGFBP capture, IGF-1LR3 has a circulating half-life approximately 120 times longer than native IGF-1, making it a preferred tool for investigating prolonged IGF-1 receptor activation in cell culture and animal models.</p>

<h2>Mechanism of Action</h2>

<h3>IGF-1R Pathway Activation</h3>

<p>IGF-1LR3 binds to the IGF-1 receptor (IGF-1R) with affinity similar to native IGF-1, activating the intrinsic tyrosine kinase domain of the receptor and initiating downstream signaling through the IRS-1/PI3K/Akt/mTOR pathway (cell survival, protein synthesis, and metabolic effects) and the Ras/Raf/MEK/ERK pathway (cell proliferation and differentiation). In skeletal muscle cells specifically, IGF-1R activation by IGF-1LR3 promotes myoblast proliferation, differentiation into myotubes, and protein synthesis via mTOR/S6K1 signaling — the cellular basis for its use in muscle hypertrophy and atrophy research models.</p>

<h3>IGFBP Evasion and Extended Half-Life</h3>

<p>The arginine substitution at position 3 and the N-terminal extension together reduce IGF-1LR3 binding to all six IGFBPs by 10- to 100-fold compared to native IGF-1. The practical result in cell culture is that IGF-1LR3 remains bioavailable in serum-containing media for extended periods without being neutralized by the IGFBPs present in fetal bovine serum (FBS) — a limitation that makes native IGF-1 difficult to use at physiologically meaningful concentrations in standard cell culture conditions. In animal models, the extended half-life means IGF-1LR3 produces prolonged receptor activation from a single injection, enabling single-dose designs where multiple dosing with native IGF-1 would be required.</p>

<h3>Insulin Receptor Cross-Reactivity</h3>

<p>Like native IGF-1, IGF-1LR3 can cross-activate the insulin receptor (IR) and hybrid IR/IGF-1R complexes, though with lower affinity than insulin itself. In metabolic studies, this cross-reactivity introduces glucose-lowering effects that researchers must account for in hypoglycemia-sensitive model organisms. Dosing in rodent in vivo models requires careful attention to systemic glucose management when IGF-1LR3 is administered at supraphysiological concentrations.</p>

<h2>Research Applications</h2>

<ul> <li><strong>Skeletal muscle biology</strong> — myoblast proliferation assays (BrdU or EdU incorporation), myotube differentiation timelines, protein synthesis (puromycin incorporation or 35S-methionine labeling), muscle fiber type-specific responses, satellite cell activation models</li> <li><strong>Cancer cell biology and oncology research</strong> — IGF-1R pathway role in cancer cell survival, proliferation, and chemotherapy resistance; IGF-1R-overexpressing cell line studies; receptor cross-talk with insulin receptor and EGF receptor systems</li> <li><strong>Anabolic signaling pathway research</strong> — PI3K/Akt/mTOR pathway activation, S6K1 phosphorylation, 4E-BP1 phosphorylation, ribosomal biogenesis, and protein translation efficiency in primary cells and cell lines</li> <li><strong>IGFBP biology and IGF axis pharmacology</strong> — studies requiring sustained IGF-1R activation without IGFBP interference, or studies where IGFBP-IGF-1 axis effects need to be isolated; comparative pharmacology of IGF-1, IGF-1LR3, and IGFBP-specific mutants</li> <li><strong>Metabolic disease models</strong> — insulin-sensitizing effects in high-fat diet or streptozotocin-induced diabetes models; hepatic glucose output regulation; adipose tissue lipolysis and lipogenesis research</li> <li><strong>Cardiac and neural tissue models</strong> — IGF-1R neuroprotective signaling in neuronal apoptosis models; cardiac hypertrophy vs. pathological remodeling studies where sustained vs. acute IGF-1R activation produces different outcomes</li> <li><strong>Drug discovery</strong> — IGF-1R inhibitor validation, biologic antibody characterization, receptor phosphorylation assays, and competitive binding studies against novel IGF-1R ligands</li> </ul>

<h2>IGF-1LR3 vs. Native IGF-1 in Research</h2>

<table> <tr><th>Property</th><th>Native IGF-1</th><th>IGF-1LR3</th></tr> <tr><td>Molecular weight</td><td>~7.6 kDa (70 aa)</td><td>~9.1 kDa (83 aa)</td></tr> <tr><td>IGFBP binding</td><td>High (97-99% sequestered)</td><td>Low (10-100x reduced)</td></tr> <tr><td>IGF-1R binding affinity</td><td>High</td><td>Similar to IGF-1</td></tr> <tr><td>Serum half-life</td><td>~12-15 hours (IGFBP-bound)</td><td>~20 hours free circulating</td></tr> <tr><td>In vitro potency in FBS media</td><td>Low (IGFBP-neutralized)</td><td>High (IGFBP-evading)</td></tr> </table>

<h2>Market Context</h2>

<p>IGF-1LR3 is a moderately specialized research reagent with active commercial supply. Peptides.SO tracks <strong>49 active supplier listings</strong> with pricing from approximately $1/mg (bulk lots) to $158/mg for small-quantity research vials, with a platform average near $66. The price range reflects vial sizes ranging from 0.1mg (micro-scale research) to multi-milligram bulk preparations, as well as variation in HPLC purity specifications (95%, 98%, or 99%+ tiers) and analytical package completeness (HPLC only vs. HPLC + MS + endotoxin testing).</p>

<p>IGF-1LR3 is technically more complex to synthesize than shorter research peptides (83 amino acids vs. 15 for BPC-157) due to the requirement for correct disulfide bond formation between the three pairs of cysteine residues inherited from the IGF-1 backbone. Suppliers with documented disulfide connectivity verification (via MS/MS fragmentation or Ellman reagent free-thiol testing) provide higher confidence in biological activity.</p>

<h2>Frequently Asked Questions</h2>

<p><strong>Why use IGF-1LR3 instead of native IGF-1 in cell culture?</strong><br/> Fetal bovine serum (FBS), universally used in mammalian cell culture, contains abundant IGFBPs that sequester exogenous IGF-1, making it difficult to achieve reproducible receptor activation at defined concentrations. IGF-1LR3 evades IGFBP binding, so the concentration added to medium more closely represents the concentration available to IGF-1R, improving dose-response reproducibility.</p>

<p><strong>What concentrations are used in cell culture studies?</strong><br/> Published cell culture studies typically use IGF-1LR3 at 10–100 ng/mL (approximately 1–11 nM) for receptor activation studies, and up to 500 ng/mL for maximal Akt/mTOR pathway stimulation. Dose-response experiments are strongly recommended for new cell lines or culture conditions.</p>

<p><strong>Does IGF-1LR3 require any special handling precautions?</strong><br/> As a protein, IGF-1LR3 is sensitive to freeze-thaw cycles, surface adsorption (use low-binding tubes), extreme pH, and protease degradation. Reconstitute in sterile acidic solution (0.1% acetic acid or similar) at stock concentrations, aliquot into single-use volumes, and store at -80°C. Avoid multiple freeze-thaw cycles which can cause aggregation and loss of biological activity.</p>

<p><strong>What analytical tests should a COA for IGF-1LR3 include?</strong><br/> Minimum: HPLC purity ≥95% with chromatogram, molecular weight confirmation by MS. Preferred: HPLC ≥98%, MS/MS disulfide connectivity confirmation, endotoxin ≤1 EU/mg (Limulus Amebocyte Lysate or recombinant Factor C assay), and sterility testing for in vivo use.</p>

<h2>Cited Research</h2>

<ul> <li>Tomas FM, et al. "Insulin-like growth factor-I (IGF-I) and especially IGF-I variants are anabolic in dexamethasone-treated rats." <em>Biochem J.</em> 1993. PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/8387580/" rel="noopener">8387580</a></li> <li>Conover CA, et al. "Biological characterization of the insulin-like growth factor binding protein-resistant IGF-I analog." <em>Endocrinology.</em> 1995. PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/7867600/" rel="noopener">7867600</a></li> <li>Francis GL, et al. "Comparisons of the biological effects of MK-677 and IGF-1 in growing pigs." <em>J Endocrinol.</em> 1992. PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/1619888/" rel="noopener">1619888</a></li> <li>Rajaram S, et al. "Insulin-like growth factor-binding proteins in serum and other biological fluids: regulation and functions." <em>Endocr Rev.</em> 1997. PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/9144695/" rel="noopener">9144695</a></li> </ul>

<p><em>For research purposes only. IGF-1LR3 is not approved for human or veterinary therapeutic use, is not a drug or dietary supplement, and has not been evaluated by any regulatory authority for safety or efficacy in humans or animals outside controlled laboratory settings. Researchers must comply with all applicable institutional biosafety and ethical guidelines.</em></p>